DS bullish in outlook, shame there was no mention of maiden sales of Inavir
"Daiichi Sankyo Co. Ltd. (4568.TO) said Monday its net profit grew 34% in the October-December quarter due to higher global sales of its blood pressure-lowering drug and strong earnings from its Indian generic drug unit Ranbaxy Laboratories Ltd. (500359.BY)."
http://online.wsj.com/article/BT-CO-20110131-700226.html
DS bullish in outlook, shame there was no mention of maiden...
-
- There are more pages in this discussion • 37 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)